Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Under-reporting of severe and serious Adverse Events Following Immunization (AEFIs) from tertiary care teaching hospitals is a pressing issue in India. This pilot study aimed to evaluate the feasibility of a smartphone-based reporting intervention to enhance AEFI surveillance by treating doctors in four public teaching hospitals in Chennai, India.

Methods: From August 2023 to March 2024, a digital intervention was implemented across four medical college hospitals involving pediatrics, community medicine, and pharmacology departments. The intervention included: [1] designation of nodal officers, [2] awareness and skill-building workshops for faculties and PG scholars, [3] deployment of a smartphone-based AEFI case notification application, and [4] visual job aids. Mobile app usage, Case Notification Form submissions, and national AEFI surveillance platform documentation were analyzed for feasibility using Terezi et.al 2022 framework with predefined progression criteria.

Results: A total of 179 doctors registered as notifiers; 27 unique notifiers submitted 56 pediatric serious and severe AEFI case notifications from November 2024 - March 2025. Post-notification, 2 cross-notified to other states and 1 discarded, led to 53 cases (100 %) that were successfully documented in the national Surveillance and Action for Events following vaccination (SAFE-VAC) portal with the case ID, case reporting, and investigation forms. All reporters are from the Pediatrics department. Most notifiers were postgraduate scholars, 23/27 (85 %). 16/56 (26 %), and 36/56 (64.2 %) CNFs reported on the same day and within four days of case identification, respectively. Key challenges included confusion on case notification form fields and incorrect documentation of vaccination site details, which were addressed through refresher training and individualized support.

Conclusions: The smartphone-based notification system for serious and severe AEFI was feasible, acceptable, and can effectively complement the passive AEFI surveillance systems. Engaging teaching hospitals through digital tools and tailored support offers a scalable strategy to strengthen AEFI reporting in low-resource settings.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2025.127644DOI Listing

Publication Analysis

Top Keywords

teaching hospitals
16
aefi surveillance
12
case notification
12
adverse events
8
events immunization
8
treating doctors
8
tertiary care
8
care teaching
8
hospitals chennai
8
india pilot
8

Similar Publications

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.

Bone Marrow Transplant

September 2025

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres.

View Article and Find Full Text PDF

Availability of benign missense variant "truthsets" for validation of functional assays: Current status and a systematic approach.

Am J Hum Genet

September 2025

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK. Electronic address:

Multiplex assays of variant effect (MAVEs) provide promising new sources of functional evidence, potentially empowering improved classification of germline genomic variants, particularly rare missense variants, which are commonly assigned as variants of uncertain significance (VUSs). However, paradoxically, quantification of clinically applicable evidence strengths for MAVEs requires construction of "truthsets" comprising missense variants already robustly classified as pathogenic and benign. In this study, we demonstrate how benign truthset size is the primary driver of applicable functional evidence toward pathogenicity (PS3).

View Article and Find Full Text PDF

Purpose: To evaluate whether AI-assisted ipsilateral tissue matching in digital breast tomosynthesis (DBT) reduces localization errors beyond typical tumor boundaries, particularly for non-expert radiologists. The technology category is deep learning.

Materials And Methods: The study consisted of two parts.

View Article and Find Full Text PDF

Background: Online postal self-sampling (OPSS) allows service users to screen for sexually transmitted infections (STIs) by ordering a self-sampling kit online, taking their own samples, returning them to a laboratory for testing, and receiving their results remotely. OPSS availability and use has increased in both the United Kingdom and globally the past decade but has been adopted in different regions of England at different times, with different models of delivery. It is not known why certain models were decided on or how implementation strategies have influenced outcomes, including the sustainability of OPSS in sexual health service delivery.

View Article and Find Full Text PDF

Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.

View Article and Find Full Text PDF